Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies

Antivir Ther. 2016;21(5):465. doi: 10.3851/IMP3073. Epub 2016 Aug 10.

Authors

Marianne Martinello¹, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Barbara Yeung, Laurence Maire, David Iser, Andrew Lloyd, Alexander Thompson, Joe Sasadeusz, Paul Haber, Gregory J Dore, Gail V Matthews

Affiliation

¹ Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW Australia, Sydney, NSW, Australia. mmartinello@kirby.unsw.edu.au.

PMID: 27509356
DOI: 10.3851/IMP3073

No abstract available

MeSH terms

Clinical Trials as Topic*
Hepacivirus
Hepatitis C / drug therapy*
Hepatitis C, Chronic / drug therapy
Humans